ESMO, Barcelona, 3 July 2013
description
Transcript of ESMO, Barcelona, 3 July 2013
![Page 1: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/1.jpg)
ESMO, Barcelona, 3 July 2013
Pascal HAMMEL, MD, PhD
Department of Gastroenterology- Pancreatology Hôpital Beaujon
92110 ClichyFrance
The optimal algorithm for diagnosis and for obtaining a biopsy in pancreatic
cancer
![Page 2: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/2.jpg)
Disclosure form
No conflict of interest in relation with this lecture
![Page 3: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/3.jpg)
1- Take clinical context into account
2- Do not trust too much serum markers
3- Discuss biopsy- When ?- How ?- What results ?
4- Future demands for biopsy
Diagnosis of pancreatic cancer
![Page 4: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/4.jpg)
- Differential diagnosis can be difficult, consequences of errors very deleterious
- Importance of : age, general status, tobacco/alcohol consumption, history of pancreatitis, changes in weight, diabetes, familial history of cancers (digestive, gynecologic,
skin)
1- Take clinical context into account
![Page 5: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/5.jpg)
1- Take clinical context into account
2- Do not trust too much serum markers
3- Discuss biopsy- When ?- How ?- What results ?
4- Future demands for biopsy
Diagnosis of pancreatic cancer
![Page 6: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/6.jpg)
2- Do not trust too much serum markers
CA 19.9 False - False +
Causes . Phenotype Lewis b - • benign cholestasis• chronic pancreatitis (50 %)• liver cirrhosis (60%)• Diabetes•Other cancers :
- biliary (70%), stomach (50%),
colon (30%), oesophagus (10%), non digestive (14%)
Comments • 7-10% of the population• No CA 19.9 on cells surface (even when pancreatic cancer)• CA 19.9 not measurable (< 3U/mL)
• Values can be very high in common bile duct obstruction whatever cause (> 1000 U/mL)•Diabetes : moderate elevation (2-3N), correlation between CA 19.9 and HbA1c
Magnani J Biol Chem 1982 Steinberg Am J Gastroenterol 1990
![Page 7: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/7.jpg)
2- Do not trust too much serum markers
CA 19.9 False - False +
Causes . Phenotype Lewis b - • benign cholestasis• chronic pancreatitis (50 %)• liver cirrhosis (60%)• Diabetes•Other cancers :
- biliary (70%), stomach (50%),
colon (30%), oesophagus (10%), non digestive (14%)
Comments • 7-10% of the population• No CA 19.9 on cells surface (even when pancreatic cancer)• CA 19.9 not measurable (< 3U/mL)
• Values can be very high in common bile duct obstruction whatever cause (> 1000 U/mL)•Diabetes : moderate elevation (2-3N), correlation between CA 19.9 and HbA1c
Magnani J Biol Chem 1982 Steinberg Am J Gastroenterol 1990
![Page 8: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/8.jpg)
2- Do not trust too much serum markers
Insuffisant validation, feasibility in routine practice,
problems of sensitivity/specificity
- KRAS (Maire, BJC 1998)
- p53 (Hammel, Gut 1997)
- Circulating tumor cells (Iwanicki-Caron I Am J Gastroenterol 2013, Clement-Bidard
Ann Oncol 2013)
- Others : CYFRA 21-1 (Boeck, BJC 2013), miR-27a-3p (Wang, Cancer Prev
Res 2013), LCN2/TIMP1 (Slater, Translational Oncology 2013), serum metabolomics
(Kobayashi, Cancer Epidemiol Biomarkers Prev 2013), PAM04 (Gold DV, ASCO GI 2010)
… or specificity with jaundice (Tonack S, BJC 2013)
![Page 9: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/9.jpg)
Focal pancreatitis
- Long/incomplete
- Different level CBD
Cancer
- Short /complete
- Same level CBD
Pseudotumour : length of MPD stenose
PMPD : Main pancreatic duct CBD : common bile duct
CBDMPD CBD
MPD
2- Can we trust imaging methods ?
![Page 10: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/10.jpg)
Suspicion of cancer on MRI : pitfall
Suspect « stop » and upstream enlargement of MPD
![Page 11: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/11.jpg)
To detect calcifications in chronic pancreatitis : CT scan > MRI
Suspicion of cancer on MRI : pitfall
CT CT
![Page 12: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/12.jpg)
Chronic pancreatitis often present beside a cancer…
In a segment of pancreas, focal enlargement of main pancreatic
duct upstream a mass
… Chronic pancreatitis : risk factor for cancer (x 10-15)
Pancreatic mass on imaging : pancreatitis or cancer ?
Relative risk high….but less than 5% of patients with old CP
Chronic pancreatitis silent for long time becomes symptomatic again
Calcifications are «pushed » around the mass
Extrapancreatic spreading of the tumour
![Page 13: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/13.jpg)
• PET-18FDG– Sensitivity and specificity in cancer
do not exceed 80%
Schick, Eur J Med Mol Imaging 2008 Kartalis Eur Radiol 2009:
Dietrich Clin Gastroenterol Hepatol 2008
2- Can we trust imaging methods ?
![Page 14: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/14.jpg)
• PET-18FDG– Sensitivity and specificity in cancer
do not exceed 80%
– Strong and diffuse signal
in some benign pancreatitis
– False negatives in diabetesSchick, Eur J Med Mol Imaging 2008
Kartalis Eur Radiol 2009:Dietrich Clin Gastroenterol Hepatol 2008
2- Can we trust imaging methods ?
Steroid test
![Page 15: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/15.jpg)
Locally advanced cancer (biopsy)
Screening of relative at risk for pancreatic cancer : islet of Pan-IN 3
Endoscopic Ultrasonography (EUS) in experienced hands remains one of the best tools for diagnosis
2- Can we trust imaging methods ?
Courtesy Dr Palazzo
![Page 16: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/16.jpg)
• Contrast (E)US– Hypovascularization 57/62– Differential diagnosis AIP/pNET
• Elastometry EUSCourtesy Dr L. Palazzo
2- Can we trust imaging methods ?
![Page 17: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/17.jpg)
1- Take clinical context into account
2- Do not trust too much serum markers
3- Discuss biopsy- When ?- How ?- What results ?
4- Future demands for biopsies
Diagnosis of pancreatic cancer
![Page 18: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/18.jpg)
Gut 2008;57:1646-7
Unappropriateresectionfor pancreatitis
Propose steroidsin a patient with cancer
1- Adenocarcinoma is much more frequent than pseudotumoral pancreatitis !
2- Do not hesitate to perform biopsy when doubtful
Pancreatic tumour and biopsy : why ?
![Page 19: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/19.jpg)
Pain, jaundice
Imaging (US, CT, MRI, /+-EUS) : mass
Benign or malignant ?
Likely malignant (local signs, metastases)
Type ? Adenocarcinoma
Specific management
Pancreatic tumour and biopsy : when ?
no (pNET, autoimmune pancreatitis)
![Page 20: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/20.jpg)
Pain, jaundice
Imaging (US, CT, MRI, /+-EUS) : mass
Benign or malignant ?
Likely malignant (local signs, metastases)
Resectable ?Patient eligible ?
no
Chemotherapy (CRT) or BSC
Type ? Adenocarcinoma
yes
Specific management
Biopsy
no (pNET, autoimmune pancreatitis)
Pancreatic tumour and biopsy : when ?
![Page 21: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/21.jpg)
Pancreatic tumour and biopsy : when ?
Pain, jaundice
Imaging (CT, MRI, EUS) : mass
Benign or malignant ?
Likely malignant (locoregional signs, metastases)
Resectable ?Patient eligible ?
Neoadjuvant treatment ?
no
yes
biopsy
no
resectionChemotherapy/BSC
yes : surgery envisaged
Type ? Adenocarcinoma
no (pNET, autoimmune pancreatitis)yes
Specific management
biopsy
![Page 22: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/22.jpg)
Conventional
EUS-FNA
Cytology
monolayer
Courtesy Pr Couvelard
Pancreatic cancer : remind the limits of pathology
![Page 23: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/23.jpg)
Conventional Conventionalhistology
EUS-FNA
Cytology Microfragments
monolayer Histology « cell-block »
Courtesy Pr CouvelardInformations needed : clinical context, conditions of FNA
Pancreatic cancer : remind the limits of pathology
![Page 24: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/24.jpg)
Blue Alcian
Mucus
Pancreatic cancer : remind the limits of pathology
Often poor material
![Page 25: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/25.jpg)
Pancreatic tumour and biopsy : how ?
EUS-fine needle aspiration is not always the best tool !
![Page 26: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/26.jpg)
Biopsy : more than « usual » histology ?
• In the near future, to only assess cancer will not be sufficient…
Informations required for predictive, prognostic markers
Courtesy Dr J. Cros
![Page 27: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/27.jpg)
EUS-FNA : more than « usual » histology with EUS-FNA?
hENT1Courtesy Dr J. Cros
![Page 28: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/28.jpg)
hENT1
Problem of tumour heterogeneity
EUS-FNA : could we do more than « usual » histology ?
Courtesy Dr J. Cros
![Page 29: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/29.jpg)
EUS-FNA : could we do more than « usual » histology ?
SPARC in the stroma and nab-paclitaxel
Mantoni T et al, Cancer Biology and Therapy 2008
![Page 30: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/30.jpg)
EUS-FNA : could we do more than « usual » histology ?
Biological differences between primary and metastases ?
Changes during the course of disease ?
![Page 31: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/31.jpg)
Take home messages
• Diagnosis of pancreatic cancer remains difficultto assess
• Clinical context is important
• Limitations of serum markers and imaging methods
![Page 32: ESMO, Barcelona, 3 July 2013](https://reader035.fdocuments.in/reader035/viewer/2022062500/56815952550346895dc69130/html5/thumbnails/32.jpg)
Take home messages
• Diagnosis of pancreatic cancer remains difficultto assess
• Clinical context is important
• Limitations of serum markers and imaging methods
• Most convenient route for biopsy andclose collaboration with pathologist
• Future: optimise analyses of material obtain